Technical Data
A2275-59B
APP, NT (Amyloid beta A4 Protein, APP, ABPP, Alzheimer Disease Amyloid Protein, Cerebral Vascular Amyloid Peptide, CVAP, Protease Nexin-II, PN-II, APPI, PreA4, A4, AD1)
Description:
Amyloid Beta-protein/amyloid A4 or amyloid Beta-peptide is derived from the amyloid Beta-precursor protein. Beta-amyloid is an extracellular filamentous protein component of amyloid cores, neuritic plaques and is also found as a deposit in neurofibrillary tangles. In man, Alzheimer's disease is the most common cause of senile dementia and is characterizes by abnormal filamentous protein deposits in the brain. Beta-amyloid deposits are also detected in Lewy body dementia, Down's syndrome, amyloidosis (Dutch type) and in the Guam Parkinson-Dementia complex.

Applications:
Suitable for use in Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG1,k12K248Affinity Purified
SizeStorageShippingSourceHost
500ug-20CBlue IceHumanMouse
Concentration:
Not determined
Immunogen:
Full length human beta amyloid peptide 43
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a lyophilized powder from 0.01M PBS, pH 7.2. Reconstitute in ddH2O to 1mg/ml.
Specificity:
Recognizes the N-terminal sequence of human beta amyloid peptides.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.